Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 29.72
- Piotroski Score 3.00
- Grade Overweight
- Symbol (ITCI)
- Company Intra-Cellular Therapies, Inc.
- Price $85.37
- Changes Percentage (-0.32%)
- Change -$0.27
- Day Low $84.38
- Day High $86.05
- Year High $93.45
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $100.00
- High Stock Price Target $107.00
- Low Stock Price Target $70.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.16
- Trailing P/E Ratio -58.97
- Forward P/E Ratio -58.97
- P/E Growth -58.97
- Net Income $-139,674,000
Income Statement
Quarterly
Annual
Latest News of ITCI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's What Analysts Are Forecasting For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) After Its Third-Quarter Results
Intra-Cellular Therapies' shares surged 14% after its latest quarterly results, with analysts forecasting a 52% revenue increase by 2025. Earnings per share are expected to rise, indicating a bullish ...
By Yahoo! Finance | 2 weeks ago -
Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds
The article discusses the top mid-cap stocks favored by hedge funds, focusing on Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), ranking 8th....
By Yahoo! Finance | 1 month ago -
Analysts Expect Breakeven For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Before Long
Intra-Cellular Therapies, Inc., a biopharmaceutical company, is approaching breakeven with analysts predicting profitability in 2025 after a loss of US$140m in the previous year. The company's debt-fr...
By Yahoo! Finance | 4 months ago
